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Background: Minimally invasive non-surgical techniques have ben widely used worldwide 
to treat musculoskeletal injuries. Of these techniques, injectable pharmaceutical agents are 
the most commonly employed treatments, with corticos eroids being the most widely used 
drugs. The aim of this article is to review current scientific evidence as well as the effective-
ness of minimally invasive non-surgical techniques, either alone or combined, for the treat-
ment of plantar fasciitis.  
Methods: This systematic review was conducted from April 2016 until March 2017, in ac-
cordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) statement and was registered with PROSPERO. Randomized controlled trials 
(RCTs) of adult patients diagnosed with plantar fasciiti  were included as well as intervention 
studies, with a minimal sample size of 20 subjects per study (10 per group). Assessment of 
study eligibility was developed by three reviewers independently in an unblinded standard-
ized manner. The physiotherapy evidence database (PEDro) scale was used to analyse the 
methodological quality of studies. 
Results: Twenty-nine full-text articles on minimally invasive techniques were reviewed. 
These articles focused on corticosteroid injections, platelet-rich plasma, Botox, dextrose in-
jections, as well as comparative studies with dry needling vs sham needling.  
Conclusion: The treatment of plantar fasciitis has dramatically improved in the past decade 
with minimally invasive techniques becoming increasingly available. Research findings have 














shock wave therapy, botulinum toxin type-A injections, platelet-rich plasma injections and 
intratissue percutaneous electrolysis dry needling show similar and sometimes better results 
when compared to only corticosteroid injections. The latter have been the mainstay of treat-
ment for many years despite their associated side effects both locally and systemically. To 
date, there is no definitive treatment guideline for plantar fasciitis, however the findings of 
this literature review may help inform practitioners and clinicians who use invasive methods 
for the treatment of plantar fasciitis regarding the levels of evidence for the different treat-
ment modalities available.  
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Plantar heel pain (PHP) is one of the main sources of complaint in the general population, 
affecting approximately 2 million Americans each year and as much as 10% of the popula-
tion over the course of a life-time (Martin et al., 2014; McPoil et al., 2008). Plantar heel pain 
may include different sources of pain, and involves different diagnoses such as myofascial 
pain syndrome, plantar fasciitis or neuritis, amongst others. Although there are few high qual-
ity epidemiological studies available, one study conducted in the United States between 1995 
and 2000 found that consultations for PHP equalled approximately one million patient visits 
to physicians per year (Riddle and Schappert, 2004).  
Plantar fasciitis (PF) is the most common cause of chronic pain beneath the heel in adults and 
may be treated using different therapeutic strategies (Martin et al., 2014; McPoil et al., 2008). 
Conservative treatments have always been the first approach for treating PF, as recommended 
by the APTA (Martin et al., 2014; McPoil et al., 2008). However, in some cases, minimally 
invasive therapies such as corticosteroid injections (Grice et al., 2017; Karls et al., 2016; 
Yucel et al., 2009), platelet-rich plasma (Ragab and Othman, 2012; Sharma, 2013; van 
Egmond et al., 2015; Moraes, 2013; Franceschi et al., 2014; Lee, 2013; Monto, 2014b; 
Monto, 2013), botulinum toxin (Venancio Rde, 2009; Diaz-Llopis et al., 2013), acupuncture 
(Zhang et al., 2011; Tough, 2009; Barbagli, 2003; Abbasoğlu et al., 2015), dry needling 
(Cotchett et al., 2014a; Cotchett et al., 2014b; Cotchett, 2014; Eftekharsadat et al., 2016) and 
prolotherapy (Kim and Lee, 2014; Demir et al., 2015) have been used. Also, a recent meta-
















The aim of this study was to review the current scientific evidence regarding minimally inva-
sive non-surgical techniques for PF. 
METHODS 
This systematic review was conducted from April 2016 to March 2017. Its purpose was to 
answer the following question: what is the effectiveness of minimally invasive non-surgical 
interventions, either alone or combined for the treatment of plantar fasciitis? The review was 
conducted in accordance with the Preferred Reporting System Items for Systematic Reviews 
and Meta-analyses (PRISMA) statement, and was registered with PROSPERO 
(CRD42018083734). 
Design 
A systematic review of scientific studies was conducted for the treatment of plantar fasciitis 
using minimally invasive non-surgical interventions. 
Search strategy: 
Our literature search aimed to identify all available experimental studies evaluating the inva-
sive non-surgical management of PF. Searches of MEDLINE, Web of Science, Cochrane, 
and PEDro databases were conducted. The last search w s performed in March 2017. The 
search strategy was: ((Efficacy OR management OR effectiveness) AND (plantar OR fasciitis 
OR fasciosis OR fascitis OR heel) AND (dry need* ORintratissue percutaneous electrolysis 
or acupuncture or electroacupuncture or injection or injectabl* or puncture and infiltrat*)). 
These keywords were identified after preliminary literature searches. There was no restriction 
by date. The inclusion criteria were: 1) Randomized controlled clinical trials with a sample 
size of at least 20 subjects per study (10 per group); 2) Age of subjects: 18 years and older; 3) 
Diagnosis of plantar fasciitis (or equivalent terms such as fasciosis or fascitis or heel pain); 4) 














needling and/or injections, acupuncture, infiltration). The exclusion criteria were: 1) Any 
study including a surgical procedure or pharmacological oral agents or topical ointment; 2) 
Studies with animals 3) Trials whose sample or participants included any of the following 
terms: diabetes, spasticity, neuropathy, tumour, fracture, haemophilia, stroke, amputation, 
artificial limbs and rheumatoid arthritis; 4) Articles for which the full text was not in English; 
5) RCTs not reaching a score of 5 in the PEDro scale (Figure 1). The evaluation of the eligi-
bility of the studies was carried out by three independent reviewers (ZA, ML, MA) who did 
an initial filter by title, a second filter by abstract and subsequently compared the results. In 
case of disagreements, a fourth reviewer was consulted (EG). Thereafter, the full text of se-
lected articles was read to verify whether they metth  inclusion and exclusion criteria. Sub-
sequently, they were evaluated with the PEDro scale and those obtaining less than 5 points 
were excluded. For the data extraction, a table was generated containing all the results classi-
fied by the outcome measurements, which helped to group the results and enabled a compari-
son amongst the different studies. 
PLACE FIGURE 1 HERE  
 
Evaluation of risk of bias 
We evaluated articles using the Physiotherapy Evidence Database (PEDro) Scale checklist 
 (https://www.pedro.org.au/wp-content/uploads/PEDro_scale.pdf) for RCTs (figure 2). In the 
PEDro checklists, each article is scored as “high quality, low risk of bias,” “acceptable quali-
ty, moderate risk of bias,” “low quality, high risk of bias,” or “unacceptable quality” which 
resulted in rejection. We defined each level based on scoring the checklists by assigning a 
value of 0 or 1 for each “no” or “yes” response, resp ctively. 















For RCTs, checklists had 10 items and quality scores w re assigned as follows: high 
quality, low risk of bias, 9-10; acceptable quality, moderate risk of bias, 6-8; low qual-
ity, high risk of bias, 3-5; unacceptable (reject), 0-2 (Fig 3). 
At least three investigators evaluated each article. If there was disagreement between 
reviewers, a fourth investigator reviewed the paper and the majority rating was used 
after discussion among reviewers. Studies of unacceptable quality were excluded from 
the evidence tables.  
Data extraction  
Data were extracted from all included studies by at le st three investigators, with one serving 
as the primary extractor and the second and third ve ifying the data. Disagreements were re-
solved by discussion, including a fourth reviewer if necessary. The extracted data were en-
tered into a Microsoft Word table grouped by the condition as outlined in the included studies 
(table 1). Items included on the data extraction form were as follows: study identification 
(first author); participants (dosage, gender, age, number of treatment sessions over period); 
comparator (age, dosage, number of treatment sessions over period); pain and functional 
outcome measures used; results (in terms of pain and functional outcomes); conclusions, 
(possible side effects). 
PLACE TABLE 1 HERE  
 
A total of 1141 studies were identified from the databases. Following inspection of the arti-
cles, 734 articles were excluded due to the language or other exclusion criteria. Studies fol-














Further analysis of the remaining text yielded 29 articles which fulfilled the inclusion criteria 
(figure 3). 
 
PLACE FIGURE 3 HERE  
 
We scored the 29 articles using the PEDro scale and excluded studies that obtained less than 
6 points (n=1). All the trials included had a score f more than 5 in the PEDro scale (tables 2 
and 3). 
PLACE TABLE 2 HERE  
 
PLACE TABLE 3 HERE  
 
RESULTS 
Twenty-nine full-text articles of minimally invasive techniques were reviewed and included 
in this systemic review. These articles focused on corticosteroid injections, platelet rich 
plasma, botulinum toxin, dextrose injections, as well as comparative studies with dry nee-
dling. Each intervention claims that the patients improved, and that the pain was decreased. 
There is no superior treatment but rather a choice f interventions, as each treatment shows 
some significant improvement.  
 
Corticosteroids  
The most common treatment that has been employed ovr the past decades is corticosteroid 
injections. Our literature search of invasive methods retrieved 26 RCTs investigating the use 
of different types of corticosteroids for the treatment of plantar fasciitis. Some studies used 
long-acting corticosteroids such as dexamethasone (Ryan et al., 2014), and betamethasone 
(Li et al., 2014a), while other studies employed intermediate-acting corticosteroids such as 
methylprednisolone (Eslamian et al., 2016b; Celik et al., 2016; Canyilmaz et al., 2015; Ball et 














et al., 2015a), dopomedrol (Jain et al., 2015a) and te oxicam (Guner et al., 2013b). There was 
no significant criteria or protocol used for choosing the type of corticosteroid. A meta-
analysis conducted by Gaujoux-Viala et. al (Gaujoux-Viala et al., 2009) found no difference 
between the various types of corticosteroid used. In addition, the technique and application of 
the medication differed between the studies; some studies used a medial approach to inject 
the patients, while others used either a posterior app oach or through the plantar aspect of the 
heel pad. The approach used also depended on whether the study was conducted using the 
palpation intervention approach or under ultrasound gui ance. 
 
Botulinum Toxin Type-A  
Traditionally, botulinum toxin has been used in thereatment of spasticity and nerve blocks. 
Only recently has it found its way into musculoskeleta  medicine. Three RCTs compared the 
effect of botulinum toxin type-A (BTA) on heel pain with steroids (Huang et al., 2010a; 
Peterlein et al., 2012a; Díaz-Llopis et al., 2012). The studies reported significant improve-
ments with BTA. Furthermore, patients with plantar fasciitis who received BTA had signifi-
cantly longer lasting relief of dysfunction and pain than those who received placebo. Further 
comparative studies are needed with larger sample sizes (Ahmad et al., 2017). 
 
Autologous platelet-rich plasma therapy  
Platelet-rich plasma (PRP) therapy showed significant improvements in the 3-month follow-
up. The use of PRP improves blood flow at the site of injection, which aids in the 
regeneration at the site of pain and inflammation, a d the boost that occurs after the 
injections help the regeneration of the site of pain nd inflammation. In chronic plantar 
fasciitis, local autologous whole blood (AWB) injections were superior to conservative 














those of corticosteroids and either can be used as a second-line treatment, although the use of 
corticosteroids is associated with a slightly higher risk of complications (Jain et al., 2015b; 
Karimzadeh et al., 2017). This approach has been studied in nine RCTs for plantar heel pain 
showing that PRP injections are as effective as corticosteroids and, in most cases, superior to 
the use of corticosteroids. Some of the papers reviewed compared PRP with corticosteroid 
injections, and some with other treatment modalities.  
 
Polydeoxyribonucleotide (PDRN) injections 
Polydeoxyribonucleotide injections have clinical efficacy with no notable complications and 
were associated with symptomatic improvement in refractory plantar fasciitis. Two main 
pharmacological effects of PDRN are hypothesized: the stimulation of VEGF and a decrease 
in inflammatory cytokines, such as TNF-α and IL-6, and an increase in the anti-inflammatory 
cytokine IL-10, which could result in the treatment ffect on plantar fasciitis (Kim and 
Chung, 2015).  
 
Acupuncture 
Acupuncture has been used in Chinese medicine for hundreds of years however few RCTs 
were available in English. We retrieved two articles that used acupuncture for the relief of 
heel pain with high significant outcome, however these were based on small samples and 
were lacking evidence supporting the use of the acupuncture (Kumnerddee and Pattapong, 
2012; Zhang et al., 2009). 
 
Dry needling 
Dry needling is a more recent minimally invasive technique. Considerable research has been 














promising results with fewer side effects. The theory behind dry needling is the release of the 
myofascial trigger point (MTrP), which is a hyperirritable spot in the skeletal muscle tissue. 
The reasons for trigger point production are multifactorial and include micro-tears, smoking, 
or a lack of oxygenated blood at the site of trigger point which decreases the pH level and 
renders the site more acidic and vulnerable to changes at the cytoskeletal level as well the 
cellular level, and thus produces pain. To date, thre are few studies supporting the use of dry 
needling and its effects.  Recently, two RCTs have reported a good outcome for these patients 
with minimal side effects. Over recent years, the us of dry needling is gaining popularity 




If any future plans to update the protocol and guidelines for the treatment of plantar fasciitis 
are to be undertaken, treatment protocols should be put in place with emphasis on first- and 
second-line treatments. The concept of referred pain to the heel, which can originate from a 
myofascial trigger point, has been neglected. A more in-depth assessment of patients must be 
considered before prescribing any treatments. The needle effect was described by Lewit in 
1979, who emphasized that the trigger point can be the source of the pain.  
Clinicians should consider starting treatment with non-invasive techniques and lack of im-
provement following these techniques should indicate the need to proceed towards minimally 
invasive techniques (figure 4). 
PLACE FIGURE 4 HERE  
 
First line treatment should include exercise therapy nd one additional treatment modality, 
either shockwave therapy or manual therapy, to treat the trigger points. As a second-line 














pharmacological and show promising results. However, this technique should be investigated 
further on a bigger sample group with a longer follow-up period (Eslamian et al., 2016a).   
The use of intratissue percutaneous electrolysis has been widely used in Europe, mainly in 
Spain, however, to date, there are no published stuies comparing its effectiveness for the 
treatment of plantar fasciitis. Preliminary studies with prolotherapy are promising and this 
technique can be used if dry needling fails. Also, pr lotherapy has a better side effect profile 
compared to steroid injections. Injectable corticosteroids have been the mainstay of treatment 
for many years despite their associated side effects bo h locally and systemically (Cole and 
Schumacher, 2005). Despite this, there are no specific guidelines for the use of steroids indi-
cating the dosage, type or frequency of injections. 
Radiation therapy is another treatment approach that has been employed for pain relief of 
plantar fasciitis. Its mechanism of action is unknow , however, it is thought to have anti-
inflammatory properties in low doses which may be attributed to the pain relief seen when 
used in treatment of plantar fasciitis. Fractional doses of 0.5 to 1.0 Gy and total doses of 3-6 
Gy are employed in the treatment of plantar fasciiti . I  is important to note that radiation 
therapy is carcinogenic and patient selection is crucial as well as their informed consent 
(Canyilmaz et al., 2015). 
 
Conclusion 
Based on the findings of all the RCTs analysed, many authors consider that plantar fasciitis is 
a degenerative tissue condition rather than an inflammation at the site of origin of the plantar 
fascia at the medial calcaneal tuberosity. The histology of plantar fasciitis is the same as that 
of tendinopathies. This implies that degeneration ca  ause a micro tear within the fascia that 
does not heal, which can trigger inflammation. However an interruption in the healing 














The treatment of plantar fasciitis has dramatically improved in the past decade with more 
minimally invasive techniques becoming increasingly available. The results demonstrate that 
the long term effects of minimally invasive (non-surgical) treatments such as shock wave 
therapy, botulinum toxin type-A injections, platelet-rich plasma injections and intratissue 
percutaneous electrolysis dry needling show similar and sometimes better results when 
compared to corticosteroid injections. Most studies have been using corticosteroids which, as 
well as being associated with transient effects on pai and function, are associated with a 
number of complications, including infections, contact allergic dermatitis due to 
preservatives, skin atrophy, osteomyelitis of the calcaneus and rupture of the plantar fascia 
(Canyilmaz et al., 2015; Karimzadeh et al., 2017). Furthermore, higher doses of 
corticosteroids can be contraindicated in certain ptients (Karimzadeh et al., 2017). 
Corticosteroids, the current mainstay of plantar fasciitis treatment, are divided based on their 
duration of action and, as of yet, consensuated guielines regarding corticosteroid use are 
lacking. In conclusion, definitive treatment guidelin s for plantar fasciitis are still lacking. 
The best results were obtained by combining several t chniques with minimal invasive thera-
py such as stretching or exercises in additional to the treatment that been prescribed. 
The findings of this literature review may help inform practitioners and clinicians who use 
invasive methods for the treatment of plantar fasciiti  regarding the levels of evidence for the 
different treatment modalities available. 
 
Limitations and future study recommendations  
We have identified 29 relevant RCTs, which covered a wide variety of interventions and sev-
eral procedural approaches that can be employed to stablish treatment protocols for plantar 
heel pain. However, a wide range of dosages were used in some of the treatments (number of 














dosage. Studies should clearly describe treatment protocols, including frequency, intensity 
and duration in order to reach optimal management. Fur her research is needed to investigate 
the value of single and combined modalities. Additionally, it is possible that some studies 
were missed, despite the formal literature search.   
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Table 1. Characteristics of the included studies. 










(n=40) Age 18-65 years. 
Chronic plantar fasciitis.  
 
Group 1: (n=20) ESWT 
with (41.45 ± 8.05) 
years, 18 (90%) female. 
 2000 shock 
waves/session of 
0.2 mJ/mm(2) for 15 min, 
5 sessions in 3 days in-
tervals. Only Acetamino-
phen was recommended 




Group 2: (n = 20) local 
methylpredniso-
lone injection with the age 
of (42.85 ± 8.62) years, 
15(75%) females  
Corticosteroid injection  
40 mg local methylpredni-
solone, 1% lidocaine on 
palpation at the most ten-
der point, medial plantar or 


















[FFI decreased to 
19.65 ± 21.26 points 
(67.4% improvement) in 
ESWT vs 31.50 ± 20.53 
points (47.7%) 
in injection group at week 
8, P =  0.072)] 
 
The inter-group differ-
ences were not significant, 
FFI was enhanced more 
with ESWT and patients 
were more satisfied with 
ESWT. 
The shock-
wave therapy seems a 
safe alternative for man-
agement of chron-












(n=68) Acute plantar 
fasciitis > 18 years.  
Group 1: (n=43) CSI 
(44.68±9.20) years ,(28) 
female and (6) Male   40 
mg of methyl predniso-
lone acetate plus 1mL of 
lidocaine 2% was inject-
ed into maximal tender-
ness point at the infra 
Group 2: (n=41) ESWT 
(43.91±7.96), (29) females 
and (5) males 
ESWT 2000 impulses with 
energy of 0.15 mJ/mm, 
total energy flux density of 
900mJ/mm for consecutive 
3 sessions at 1 week inter-
vals 





The pain reduction in CSI 
group was significantly in 
those in the ESWT group 
(p<.0001). 
 
In the ESWT and CSI 
groups, 19 (55.9%) and 5 
(14.7%) patients experi-
enced treatment failure, 
respectively. Age, gender, 
ESWT and CSI can be 
used as a primary treat-
ment option for treating 
patients with acute plan-
tar fasciitis; however, the 




















the maximum tender point 
marked with a skin marker 
with an US gel applied as a 
medium. No anaesthesia or 










body mass index, and re-
currence rate were similar 
between the two groups 
(p > .05) 
 
The patient were 4 times 
more irresponsive to 
ESWT than CSI  
Canyil








is> 6 months of evolu-
tion, have calcaneal spur 
and are over 40, no pre-
vious pharmacological 
treatment is restricted. 
 
Group 1: (n=64)  Re-
ceive radiation therapy 
mean ± SD, years  
 52.6 (40-74) years, 46 
(76.7%) female 
14 (23,3%) in male.  
(A total dose of 6.0 Gy 
applied in 6 fractions of 
1.0 Gy three times a 
week). 
 
Group 2: (n=64) PG-
Steroid injection mean ± 
SD, years  




tions; A 22-gauge 1.5-inch 
needle with 40 mg of 
methylprednisolone (1 ml) 
mixed with 0.5 ml of 1% 
lidocaine. The painful area 
and medial tubercle of cal-




Functionality :  a 
modified von 
Pannewitz scale, 
and a 5-level 
function score. 
 Post treatment is:  
3 months 
Follow-up period 





low-up was 13 
months  
(PG) steroid injec
tion arm, it was 
The pre-treatment VAS 
score was higher in radia-
tion therapy: 
VAS: 7.6 in radiation 
         6.9 in PG-Steroid   
After three months, results 
in 
the radiation therapy arm 
were 
 significantly superior to 
those in the 
PG steroid injection arm 
(VAS P<.001; modified 
von Pannewitz scale, 
P<.001; 5-level function 
score, P<.001). Require-
ments for a second treat-
ment was not significant. 
This study confirms the 
better analgesic effect 
of radiation therapy com
pared to mean Palpation 
Guid-
ed steroid injection on pl
antar fasciitis for at least 
six months af-
ter treatment 


















The time intervals for the 
second treatment was sig-











Unilateral chronic PF 
whom did not respond to 




ical treatment’s.  
 
Group 1: (n=20) 9 
males, 11 females 59 
years average of age 




Both group used 2% of 
chlorhexidine, glu-
conate/70% isopropyl 
alcohol and then local 
anaesthesia. Insertion of 
the injection at the medi-
al calcaneal tubercle. 
Patients were placed into 
calm walker for 2 weeks, 
Group 2: (n=20); 51 aver-
age age (21-67 years) 8 
male and 12 females.  
 single guided US PRP  
Both group used 2% of 
chlorhexidine, glu-
conate/70% isopropyl al-
cohol and then local anaes-
thesia. Insertion of the in-
jection at the medial calca-
neal tubercle. Patients were 
placed into calm walker for 
2 weeks, allowed to return 
to activity as tolerated with 
daily home eccentric exer-
cises and calf stretch 
PRP=27 cc venous blood 
sample mixed with 3 cc of 
anticoagulation citrate dex-
trose solution formula to 
prevent clotting of the 
sample, then centrifuged at 
2400 rpm/12 minutes using 
a soft spin 
 
Pain: VAS  
Functionally:  
(AOFAS) (pre-
treatment = time 
0) and at 3, 6, 12, 






graphs and MRI 
studies were ob-
tained in all cases 









The cortisone group had 
AOFAS: score of 52 pre-
treatments, which initially 
improved to 81 at three 
months post treatment but 
decreased to 74 at six 
months, suddenly dropped 
to near baseline levels of 
58 at 12 months and pro-
ceeded to decline to a 
final score of 56 at 24 
months. 
 
The PRP group began 
with an average pre-
treatment AOFAS score of 
37, which increased to 95 
at three months, remained 
elevated at 94 at 6 and 12 
months, and had a final 
score of 92 at 24 months. 
 
PRP was more efficient 
and durable than corti-
sone injection for 
the treatment of chronic 














allowed to return to ac-
tivity as tolerated with 
daily home eccentric ex-














(n=21) with unilateral 
foot pain for more than 6 
months with chronic PF 
confirmed with an US 
(thickness >4 mm) It is 
chronic fasciitis that has 
failed conservative 
treatment even with cor-
ticosteroid injections 
before 6 months prior to 
the study, no pharmaco-
logical Treatment.  
 
Group 1: (n=10) PRP  
36.2 (20-57 years), 6 fe-
males & 4 males Whole 
blood (20 mL) was collect-
ed from the antecubital 
fossa into a 25-mL syringe 
that contained 2 mL of 
anticoagulant (Huons 
ACD-soln; sodium citrate 
22 mg, citric acid 7.3 mg, 
glucose monohydrate 24.5 
mg).  
 
Functionally: FFI  
Follow-up: Data 
collected before 
the first injection 
at 2 weeks and at 
2- and 6th month 
 
An improvement in the 
mean FFI total scores 
from 132.5 ± 31.1 at base-
line to 123.7 ±47.4 (3.8% 
improvement) at 10 weeks 
and to 97.7 ±52.5 (15.1% 
improvement) at 28 
weeks’ follow-up was 
achieved in the DP group.  
 
The main FFI improves 
were greater in PPR 
group compared with DP 
Both treatments seem to 
be effective for chronic 
recalcitrant PF, but after 
2 month. Improvement 
achieved over time with 
no adverse events accept 
of the pain after injec-
tions.   
PRP also may lead better 
initial improvements in 
















Group 2: (n=11) DP 
37.8 (19-51 years), DP 4 
females & 7 males Dex-
trose Prolotherapy, 1.5 
mL of 20% dextrose and 
0.5 mL of 0.5% lido-
caine, resulting in a 15% 
dextrose solution, within 




Injection was given in both 
group 2 times. 2 weeks and 
then after the next 2 weeks 
the second injection  
 
 Patients were kept sitting 
position for 30 minutes. 
They were sent home with 
instructions (allowing only 
indoor activities of daily 
living) for approximately 
72 hours & to use aceta-
minophen for pain. The use 
of nonsteroidal anti-
inflammatory drugs and 
any type of foot orthoses 
was not allowed.  
 
(30.4% vs.15.1%)  
Pain: 29.7 % vs.17.1%  
Disability: 26.6% 
vs.14.5% 















(n=67) with unilateral 
Chronic plantar fasciitis 
of 3 months’ duration, 
exclude those who previ-




Group 1 : (n=22)  Full 
length silicone insole 
45.6±9.3, 16 (80%) were 
female. A prefabricated 
full-length silicone insole 
daily lives for 1 month 
Group 2: (n=22) 47.4±7.9,  
16 (80%) were female 
Guided corticosteroid in-
jections 
To injection group, A 4-cm 
21-gauge needle was posi-
tioned in a caudo-cranial 
oblique manner into the 
area of maximal ultrasound 
abnormality, 1 mL of be-
tamethasone dipropionate 
(6.43 mg/ mL) and betame-
thasone sodium phosphate 
(2.63 mg/mL) combina-
Pain: first step 
heel pain via VAS 











Both groups showed sig-
nificant change in VAS at 
one month from baseline   
Injection group: 6.45 ± 
1.23 to 3.70 ± 1.45 
Insole group: 
6.95 ± 0.94 to 4.65 ± 
1.34 VAS scores were 
significantly better in 
injection group than in 






and wearing full-length 
silicone insole were ef-
fective in the conserva-
tive treatment of PF.  
 
The study recommends 
the use of silicone insole 
as the first line of treat-
ment for persons with 
plantar fasciitis. 
 














both indoors and out-
doors as possible, (acet-
aminophen) was allowed 
if necessary, except last 
24 h before evaluations. 
 
tion. Plus 1 mL lidocaine 














(n=54) with unilateral 
chron-
ic plantar fasciitis with 
more than 4 months of 
symptoms. excluding 
those who have injection 
with corticosteroids or 
another injection 4 
months before the study, 
did not exclude those 
who had physiotherapeu-
tic treatment or splints, 
all carry conventional 
treatment 
 
 3 Groups 
 
Group 3: (n=16) 47.5 
(41-53 years) 8 Male/8 
Females  
to conventional treatment
 alone.  
Convention-
al treatment included 
stretching exercises and 
orthotics if indicated. 
Group 1: ACP (n=19) age 
46 years (38-51), 10 
males/9 females.  
10 mL of peripheral blood 
drawn and centrifuged at 
1500 rpm for 5 minutes No 
buffer or preservative was 
added, per manufacturer’s 
protocol. 23-gauge, 1.5-
inch needle at a single peri-
fascial target at the site of 
plantar fascia thickening 
and tenderness at the medi-
al calcaneal tubercle.  
 
Group 2: (n=19) 45 (37-53 
years) 11 Male/8 Female to 
ESWT: 2000 shockwaves 
with energy levels pro-
gressing gradually from 
0.02 mJ/mm3 to 0.42 
mJ/mm3. The total treat-
ment duration was 10 
minutes. No local anaes-







sessed at baseline 
and 1,3,6 months 
 
ACP Group: significant 
VAS pain score improve-
ments compared with the 
conventional treatment at 
month 1 (p=.037)  
The AOFAS ankle-hind 
foot scale improved in 
ACP at third month and 
sixth month ( p=0.04 and 
p=.013) 
PF thickness was seen in 
the ACP at 1st and three 
months (p=.015 and 
p=.14)  
ESWT: 1,3,6 months 
(p=017 , p=0.22, p=0.42)  
 
The AOFAS ankle-hind 
foot scale improved in 
ESWT at the first  month 
and third  month ( p=0.11 
and p=.003) 
PF thickness was seen in 
the ACP at 1st, and three 
months (p=.019 and 
p=.027)  
ACP treatment resulted 
in greater decreases in 
ultrasound plantar fascia 
thickness than ESWT, 
The ACP treatment 
group displayed better 
objective improvements, 
when compared with the 
conventional treatment 
group at the 6-month 
follow-up. with an over-
all median decrease of 
ultrasound plantar fascia 
thickness by 1.3 mm at 
the 6-month follow-up. 
Changes in plantar fascia 
thickness more than 0.6 
mm are considered 
changes in thickness not 




No adverse events oc-























PF thickness improved in 
all groups.  
There was no significant 
difference between ACP 
& ESWT regarding VAS 
& AOFAS ankle-hind foot 
scale improvements, alt-
hough the ACP group 
showed a greater reduc-













(n=30) Chronic Fasciitis 
of 6 months of evolution 
that does not work con-
servative treatment, ex-
cluding those who have 
received injection of cor-
ticosteroids in less than 6 
month. 
 
Group 1: (n=15) 
(52.4±10.5) years, 12 
females conventional 
treatment stretching ex-
ercise, shoe modification 
and rescue analgesics 
Group 2: (n=15) 
(52.4±10.5) years, (12) 
females, 3 males. ame 
conventional plus 10 ses-
sions of electro-




(Emla) was applied 30 min 
prior treatment 2-6 needles 
were inserted at the most 
tender spot over anterome-
dial aspect no manipulation 
or twisting applied only a 
stimulated for 30 mins us-
ing the SDZ- II nerve and 
muscle stimulator  
 
Pain: VAS 
Function: FFI  
 
Endpoints includ-
ed a success rate 
determined by a 
minimum of a 
50% decrease 
(VAS) and (FFI). 
 
VAS decreased signifi-
cantly from 6.00±1.69 to 
1.89±1.59 and from 
6.27±2.34 to 5.40±2.26 in 
acupuncture and control 
group (p<0.05) acupunc-
ture group had higher suc-
cess rate than the control 
group (80% and 13.3% 
respectively) FFI was in 
acupuncture group was 
better than those control 
group (<0.001)  
 
Six week follow up acu-
puncture group showed a 
better FFI and success rate 
for pain during the day 




pled with conventional 
treatment provide success 
rate of 80% in chronic PF 
which was more effective 
than conventional treat-
ment alone, the effect 






















(n=50) unilateral chronic 
plantar fasciitis, double 
blind  
 
Group 1: (n=25) (54.4 
SD 9.6), 6:19 male to 
female. 
50 units of botulinum 




Group 2: (N=25) (51.5 5.5 
years)  Normal saline un-
der US. 1 ml normal saline, 
by injection into the plantar 
fascia under ultraso-
nographic guidance us- ing 
a 25-gauge, 1.5 inch nee-
dle. Subjects in the control 
group were injected with 1 
ml normal saline into the 
plantar fascia under ultra-
sonographic guidance.  
 
Pain: VAS  
Measuring the fat 




mal centre of 
pressure during 




Follow up three weeks 
and three months after 
Botox-A injection 
(p<0.001). 
The fat pad thickness re-
mained unchanged, the 
centre of pressure velocity 
during loading response 
increased three months 
after injection (p<0.05) 
outcome measure of the 
control group remained 
unchanged. 
BTX- A is effective in 
the treatment of foot pain 
associated with PF and 
increases the centre of 
pressure velocity during 
loading response without 









(n=100) with PF us-
ing four different method
s of local injection, pa-
tients were blinded to the 
treatment given. Exclu-
sion were if  previous 6 
months any surgery was 
done , or an abnormal 
erythrocyte sedimenta-
tion rate or C-reactive 
protein level, previous 
injections for plantar 




Group A: (n=25) Age 
(52.88±11.11), 6 males 
were treated with 2 mL 
Group C: (n=25) age 
(49.87±9.36), 8 males a 
corticosteroid (2 mL of 
triamcinolone) alone  
 
Group D: (n=25) age 
52.22±8.49, 9 males, a cor-




No additional medication 
was given, and no re-
striction of activity was 
advised. Patients were 
evaluated by re- viewers 
who were blinded to the 
study method.  
 
Pain: 10-cm VAS  
and modified cri-




Follow-up: in 3 
weeks and 6 
months after 






Successful results in all 
the groups post-treatment 
were higher than those in 
the pre-treatment condi-
tion (P = .000).  
In both C and D groups, 
in 
which local corticosteroid 
injections used, excellent 
results were obtained, 
with excellent effect in the 
group in which peppering 
was used (P < .05). 
The treatment of PF, 
combined corticosteroid 
injections and peppering 
is efficient and produces 
















of autologous blood 
alone 
Group B: (n=25) Age 
(49.92±10.8), 7 males an 
anaesthetic (2 mL of li-










(n=132) unilateral with 
manifest of 6 weeks PF. 
Exclusion of Previous 
surgery, CSI, or ESWT 
for heel pain.  
, Clinical features sug-
gestive of seronegative 
spondyloarthropathy, 
Clinical features sugges-
tive of regional pain syn-
drome.  
 
Group C: (n=19) age 
38.1 (21-61) 6 males.  
non-randomized patients 
who performed stretching 
program only 
  
All patients standardized 
a stretching program of 
the soleus, gastrocnemi-
us, and plantar fascia 
each stretch consists of 2 
min/4 times a day, ice 
massage and continuing 
Group A:  (n=64) age 39.9 
(21-80 years) 20 males 
single CSI.  
One millilitre betame-
thasone (5.7 mg) and 2 mL 
of lignocaine 1% were in-
jected into the site of max-
imal tenderness. The medi-
al calcaneal tuberosity was 
infiltrated until the patient 
declared that his/her ten-
derness and symptoms had 
gone. Patients were in-
structed not to take part in 
any running or impact ac-
tivities for at least 10 days 
following the injection.  
 
Group B: (n=61) age 38.6 
(18-81 years) 22 males 
Low dose of ESWT 3 
treatments over 3 weeks.  
Patients randomized to 
group B each received 3 
applications of 1000 pulses 
Pain: VAS, PPT  
Follow-up: base-




VAS pain scores, values 
for the CSI (1.48; 0–7) 
were significantly lower 
than both ESWT (3.69; 0–
8), and controls (3.58; 2–
5) at 3 months. At 12 
months, VAS scores for 
CSI (0.84; 0–7) and 
ESWT (0.84; 0–4) were 
both significantly lower 
than controls (2.42; 1–4). 
The tenderness values at 3 
months were significantly 
higher for CSI (9.42; 7–
11) than both ESWT 
(6.72; 4–11) and controls 
(7.63; 6–9). P< 0.05 was 
used throughout  
 
Corticoster-
oid injection is more effi-
cient and more cost-
effective than ESWT in 
the treatment of plantar 
fasciitis that has been 
symptomatic for more 
than six weeks. 
 
Of the 64 heels that re-
ceived CSI, there were no 
infections and no cases of 
rupture of the plantar 
fascia. There were 8 cas-
es of post-injection pain 
that required analgesia 















the ADL with tolerance 
to pain.  
of an energy flux density of 
0.08/mm2. 1000 impulses 
were applied 3 times at 
weekly intervals. Neither 
local anaesthesia nor seda-

























Group 1: received Dex-
trose Prolotherapy 
Group 2: corticosteroid 
injection as a single dose. 
Group 3: phonophoresis  
 
All patients were given 
exercises program.  
 
  
 Pain: VAS, THI  
Functionally: FFI 











The analysis demonstrated 
statistically significant 
improvements in all pa-
rameters from baseline to 
1 and three months (p 
<0.05). There was no sig-
nificant difference be-
tween groups regarding 
the efficacy of treatment 
(p> 0.05). 
The plantar fascial thick-
ness between the baseline 
and final measurements 
revealed a mean decrease 
in thickness, statistically 
significant difference (p 
<0.05) in three groups. 
Between groups before 
treatment, 1 and three 
months after treatment in 
terms of plantar fascia 
thickness there was no 
statistically significant 




sis therapies were well 
tolerated and appeared to 
provide the benefit of 
patients with PF. As a 
result, Prolotherapy can 
be an effective way to 
treat PF.  
 
Aside from injection-
associated pain, no ad-
verse reactions were re-
ported. 







(n=61) after 6 months of 
filed conservative treat-
ments. patients were ex-
cluded if they had frac-
ture or arthritis of the 
ankle and knee, previous 
foot surgery or trauma, 
Group 2: CSI  (n=30) 
age(56.93±9.25, 7 males, 
25 females) steroid injec-
tion  
2mL of 2% lidocaine plus 
2mL triamcinolone ace-
tonide (20 mg) was inject-
Pain: morning 
pain , (VAS) 0-10  
Follow-up: 1,6,12 




In the MSN group, the 
VAS scores for morning 
pain,  and overall pain 
were significantly im-
proved at 1, 6, and 12 
months after intervention 
compared to the baseline 
The study suggests that 
the MSN release treat-
ment is safe and has a 
significant benefit for PF 
















nerve injury, a severe 
systemic disease, contra-
lateral heel pain, or a 
history of MSN release 
treatment or local steroid 
injection  
 age (54.74±10.16), 10 
males, 19 females )  
 
Group 1: MSN (n=31) 
age (54.74±10.16), 10 
males, 19 females)  
2 mL of 2% lidocaine. 
then, the MSN(diameter 
0.80mm, length 50mm), 
inserted into the tender 
point vertically with the 
direction of the MSN 
parallel to the long axis 
of the foot. the release of 
plantar fasciitis was per-
formed by moving the 
MSN up and down 3–5 
times without rotation, 
the MSN was withdrawn, 
and pressure was applied 
to the wound for 2 min to 
avoid bleeding the hole 
was covered with a sim-
ple adhesive bandage for 
2 days.  
 
ed into the most painful 
tender point. After treat-
ment, the patients in both 
groups were observed for 
30min to record any ad-
verse reaction. All patients 
were asked to avoid bear-
ing weight on the heel pad 










scores ( < 0.01).  
 
There were no statistical 
differences in the VAS 
scores observed between 
1, 6, and but no signifi-
cant improvement in pain 
was experienced at 6 or 
12 months after interven-
tion compared to the base-
line levels ( > 0.05 )
No severe side effects 
were observed with MSN 
treatment.  The study 
suggests that MSN re-
lease treatment is safe 
and has a significant 
benefit for plantar 
























(n=75) Patients had not 
responded to at least 3 
months of conservative 
therapy, including physi-
cal therapy, NSAIDs, 
bracing, and orthotics. 
Treatment with NSAIDs 
was discontinued 1 week 





Group C (Normal sa-
line): age (35.48±9.54) 
11 males. assigned to 
receive normal saline.  
Group A (PRP): (n=25) 
age (30.72±7.42) 8 males 
was assigned to receive 
platelet-rich plasma 
27 mL of blood was with-
drawn placed in a glass 
tube containing 3 mL of 
citrate dextrose solution. 
Citrate dextrose solution 
was used to prevent clot-
ting. The blood was centri-
fuged at 3200 rpm for 12 
minutes, and 2.5 to 3 mL 
of platelet-rich plasma was 
obtained by this method. 
No activating agents were 
used. 
 
Group B (CSI): age 
(33.92±8.61) 12 males was 
assigned to receive cortico-
steroid 
2 mL of 40 mg of 
methylprednisolone was 
used for injection  
Injection was given at the 
point of maximum tender-
ness in the heel with a 22-g 




ure: VAS and 
AOFAS 
Follow-up at 3 
weeks and 3 





Mean VAS and AOFAS 
scores improved over time 
after injection in groups A 
and B.  
 
In group A, VAS score 
decreased significantly 
from the pre-injection 
level at follow-up of three 
weeks (P=0) and 3 months 
(P=0).  
 
Compared with the pre-
injection level, AOFAS 
score improved signifi-
cantly at follow-up of 
three weeks (P=0) and 3 
months (P=0). Similarly, 
in group B, VAS score 
decreased significantly 
from pre- injection level at 
follow-up of three weeks 
(P=0) and 3 months (P=0).  
The AOFAS score im-
proved significantly at 
follow-up of three weeks 
(P=0) and 3 months (P=0) 
in group B. 
 
 In group C, no significant 
difference was observed 
in  VAS score pre, and 
PRP is as effective or 
more than corticosteroid 

























post injections score at 
three weeks (P=.11); at 
three months (P=.41).  
 
There were no significant 
difference  observed be-
tween pre-injection AO-
FAS score and the score at 
three weeks (P=.06); at 
three months (P=.39) 
Craw-










(n=106) patients, above 
the age of 18 and pain 
from 1-120 months. Me-
dian duration 6 months 
(±20.6) 
excluding patient who 
received corticosteroid in 
less than 6 months.  
 
69 female and 37 males 
mean age was 57 year 
(±12.9). 
 
Group 1: (n=27), Mean: 
(53.69), SD: (14.28); 1ml 
of 25mg/ml of predniso-
lone acetate with 1 ml of 
2% lignocaine; 
 
Group 2: (n=26), Mean 
(56.88) SD: (13.02); 1 ml 
Group 3: (n=27) Mean 




Group 4: (n=26) Mean 
(58.81)  
SD: (12.48);2 ml of 1% 
lignocaine hydrochloride 
given after a 
After a tibial nerve block. 
 
 







There was a statistical 
difference between the 
groups in favour of treat-
ment with steroid at one 
month (p=0.02)  
 
No statistically significant 
difference in pain reduc-
tion could be detected 
between the injected sub- 
stances for pain outcomes 
taken at 3 and 6 months; 
the P values were 0.9 and 
0.8, respectively.  
 
No statistical difference 
existed in the numbers of 
patients lost to follow-up 
between the four groups 
(P=0.7)  
 
A steroid injection can 
provide relief from heel 
pain in the short term; 
there appears to be no 
increase in patients com-
fort from anesthetizing 
using tibial nerve block 
prior heel infiltrations. 
 
No adverse event men-














of 25 mg/ml of predniso-
lone 
acetate with 1 ml of 2% 
lignocaine given after a 
tibial nerve block 
 
 
Mean VAS score at one 
month (p=0.02)  
 
There was no statistically 
significant difference in 
pain reduction among the 
groups for pain outcomes 
taken at three months 
(p=0.9) and six months ( 
p=0.8) but thereafter no 
differences could be de-
tected. Patient comfort 
was not significantly af-
fected by anaesthesia of 





















(n=45) PHP in 3 groups, 
patients who received 
CSI last year they were 
excluded, average dura-
tion of heel pain was 19.3 
months (range, 6–180 
months).  
 
Age and Gender: 31 
Females and 14 Males. 
The mean patient age 
was 50.7 years (range, 
26–70 years)  
 
 
Group 1:(n=15) patients 
underwent the peppering 
technique  
 
Group 2: (n=15) under-
went autologous blood 
injection, a mixture of 2 
mL of autologous blood 
drawn from the ipsilat-
eral or contralateral up-
per extremity and 1 mL 
of 2% prilocaine was 
infiltrated.  
 
Group 3: (n=15) under-
went corticosteroid injec-
tion. 40 mg of 
Peppering group: In the 
peppering technique group, 
after infiltration of 1 mL of 
2% prilocaine  
the needle was inserted, 
withdrawn, slightly redi-
rected, and reinserted 10 to 
15 times with- out emerg-
ing from the skin. During 
injection, a sensation simi-
lar to crepitation due to 
dissection of the fascia or 
degenerative tissue was felt  
 
Pain: 10 cm 
VAS, Rear foot 








At six-months assessment, 
statistically significant 
improvement found in all 
groups (VAS and rear foot 
scores) there was no sig-
nificant difference among 
the three groups.  
 
Rear foot score in 6-
months:  
Peppering group: (P .018) 
Autologous blood injec-
tion: (P .025) 
Corticosteroid injection: 
(P .30)  
 
VAS score in 6-months:  







Mean ± SD visual ana-
logue scale scores in the 
peppering technique, au-
tologous blood injection, 
and corticosteroid injec-
tion groups improved 
from 6.4 ± 1.1, 7.6 ± 1.3, 
and 7.28 ± 1.2 to 2.0 ± 2.2 
The curative mechanisms 
of both injection modali-
ties based on a hypothe-
sis, they seem to be great 
alternatives to cortico-
steroid injection for the 
treatment of plantar heel 
pain  
 
















tate mixed with 1 mL of 
2% prilocaine was inject-
ed.  
 
3 injections were given to 
all groups  
 
(P < .001), 2.4 ± 1.8 (P < 
.001), and 2.57 ± 2.9 (P < 
.001), respectively. Mean 
± SD rear foot scores in 
the same groups improved 
from 64.1 ± 15.1, 71.6 ± 
1, and 65.7 ± 12.7 to 78.2 
± 12.4 (P = .018), 80.9 ± 
13.9 (P = .025), and 80.07 
± 17.5 (P = .030), respec-
tively. There were no sta-
tistically significant dif-












(n=89) onset of heel pain 
<3 months. Excluding 
needle phobic, fractures, 
pregnant and breast feed-
ing. 
 
Control group: (n=25) 
age (50.0±2.0, 6 males & 
19 females)  
The control group re-
ceived needling at the 
acupoint Hegu (LI 4), 
which has analgesic 
properties 
 
Treatment group: (n=28): 
(47.0±2.2, Males 8 & 20 
females) needling at the 
acupoint PC 7, which is 
purported to have a specif-
ic effect for heel pain 
 





There was a significant 
difference in reduction in 
pain scores, favouring the 
treatment group. 
 
At one month for morning 
pain (22.6 ± 4.0 versus 
12.0 ± 3.0, mean ± SEM). 
Overall pain (20.3 ± 3.7 
versus 9.5 ± 3.6)  
PPT (145.5 ± 32.9 versus 
-15.5 ± 39.4) 
 
The study provided that 
acupuncture can cause a 
pain relief to the patient 
with PF, The PC 7 point 
is a relatively specific 
acupoint for heel pain. 
 
No serious adverse event 






















(n=60) < 6 month of pain 
with previously field 
treatments, excluding 
previous CSI, surgery. 
Patients were allowed to 
continue their heel cup.  
 
Group B: (n=27), age 
(42.9 ± 7.08  
13 males and 14 females)   
ESWT  
A fivefold nerve block 
(posterior tibial, superfi-
cial and deep peroneal, 
sural, and saphenous 
nerves) was applied to 
each operative ankle with 
20 mL of prilocaine hy-
drochloride, 2%. Patients 
received a single applica-
tion of 3,000 shockwaves 
using an electrohydraulic 
shockwave generator. 
Com- mon ultrasound gel 
was used as a contact 
medium  
 
no additional treatment 
was permitted during the 
study period, including 
night splints, nonsteroi-
dal anti-inflammatory 
Group A: (n=33), age 
(44.7 ± 9.20, 5 males, 8 
females) CSI  
 
A 22- gauge, 1.5-inch nee-
dle was connected to a 2-
mL syringe filled with 0.5 
mL of combined betame-
thasone dipropionate (6.43 
mg/mL) and betame-
thasone sodium phosphate 
(2.63 mg/mL) (Diprospan; 
and 0.5 mL of prilocaine 
hydrochloride, 2% (20 
mg/mL) The injections 
were performed from the 
medial side of the heel. 
The most painful area over 
the medial calcaneal tuber-
osity was determined by 
palpation, and the injection 
was performed at this spot. 
Care was taken to avoid the 
fat pad and injection into 
the skin or subcutaneous 
tissues. Patients were in-
structed to refrain from 
running and impact activi-
ties for 10 days.  
 
Pain: 100-mm 








The mean visual analogue 
scale score changes were 
4.0 for group A and 5.3 
for group B (P < .05 for 
both). Both groups 
showed significant im-
provement in visual ana-
logue scale scores, but 
there were no significant 
differences in scores be-
tween the groups 3 
months after treatment (P 
> .05).  
 
Results of the visual ana-
logue scale and heel ten-
der- ness index scores 
between patients with and 
without a spur in groups A 
and B were not signifi-
cantly different (P > .05). 
Eleven of the 13 patients 
(84.6%) in group A and 
10 of the 12 patients 
(83.3%) in group B re-
sponded to therapy.  
 
ESWT and corticosteroid 
injection provided signif-
icant improvements in 
VAS and HTI scores. 
 
All of the patients in 
group A had pain during 
injection. The pain lasted 
an average of 5 days, 4 
patients required analge-
sia. No infections or oth-
er major complications 
occurred in group A.  
 
None of the patients ex-
perienced pain during the 
ESWT protocol. Two 
patients had a mild 
throbbing sensation that 
lasted an average of 5 
days, but did not require 
analgesia. Two patients 
























(n=46) with unilateral PF 
  
Group 1: (n = 22) age 
(45.4 ± 9.3), 6 male and 
14 females.  




Group 2: (n = 21) age 
(45.6 ± 7.9), 5 males & 14 
females. Stretching & mo-
bilizations + one CSI 
1mL of corticosteroids (40 
mg methylprednisolone 
acetate) or 4 mL of 2% 
(prilocaine HCL) using 22-
guage at the heel around 
the PF (no stretching was 
performed)  




baseline and at 3-
week, 6-week, 12-




in VAS & FAAM pain and 
functional outcome in only 
12 weeks and 1 year in 
group 1 (P = .002) 
Both groups were statisti-
cally significant for both 
FAAM (P = .001; F = 
7.0) and VAS (P = .001; F 
= 8.3) scores 
At 3 weeks,-6 weeks and -
12 weeks.  
 
Between-group differ-
ences in VAS & FAAM 
favoured the SI group at 
the 3-week (P = .001, P = 
.001), 6-week (P = .002, P 
= .001), and 12-week (P = 
.008, P = .001).  
 
The Steroid Injection 
group exhibited better 
outcomes at all 3-time 
points. The noted im-
provements continued  
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(n=46) heels with intrac-
table plantar fasciitis who 
had failed conservative 
treatments for 12 months 
(ESE, cushioned insole, 
physical therapy) 14 pa-
tients were treated bilat-
eral heel, 19 left heel 31 
right heel.  
 
Age & Gender: (mean 
55.6 years) 31-79 years, 
16 male  
 
Group 2:  (n=)Steroid 
injection. 
Triamcinolone (Kenalog) 
40 mg and Levobupiva-
caine hydrochloride (Chi-
rocaine) injection   
 
Group 1: (n=)PRP injec-
tions 6 underwent bilateral 
heel injection  
27 (ml) of blood was with-
drawn from the patient and 
added to 3ml of sodium 
citrate (anticoagulant). then 
centrifuge and spun for 15 
min at 3200 rpm. The 
plasma portion of the cen-
trifuged mixture was dis-
carded. Since the anticoag-
ulant introduced to the 
whole blood used to pro-
duce the platelet concen-
trate is acidic, the PRP 
portion harvested is buff-
ered with 8.4% sodium 
bicarbonate, to increase the 
Ph to normal physiological 
levels.   
 




treatment, at 3, 6 







Pre-injection, the two 
groups were well matched 
with no statistically signif-
icant difference. At three 
months, all three outcome 
scores had significantly 
improved from their pre-
treatment level in both 
groups. 
At 12 months, the RM, 
VAS and AOFAS scores in 
the PRP arm (1.9, 3.3 and 
88.5) were significantly 
better than the Steroid 
arm (2.6, 5.3 and 75) with 
P values of .013, .028 and 
.033, respectively. 
 
PRP is significantly more 
efficient than Steroid, 
making it better and more 
durable than cortisone 
injection. 
PRP is doesn’t wear off 
with time.  

























(n=40) Patients with PF, 
excluding patients un-
derwent injections within 
6 months.  
 
 
Group 2: (n=20) age 55 
(42-71 years n 4 male & 
16 females)   Placebo 








Group 1: (n=20) age was 
52 (34-68 years , 7 male & 
13 female) injection 
(PDRN)   
In the PDRN group, a half 
vial of PDRN (1.5 ml, was 
injected into the tender 
region of the heel, medial 
to the insertion of the plan-
tar fascia. In the placebo 
group, the same volume of 
nor- mal saline was inject-






at baseline and 
4,12 weeks after 
treatment began.  
 
P value represent 
pairs t-test with 









The PDRN group show a 
significant improvement in 
VAS and MOXFQ scores 
at four weeks’ post-
treatment, and this con-
tinued until 12 weeks’ 
post-treatment.  
The placebo group did not 
achieve a significant im-
provement in the VAS or 
MOXFQ scored at four or 




PDRN  is an efficient and 
safe treatment option and 
may be considered for PF 
treatment.   
 
 
We noticed no injection-
related complications, 
such as itching, urticaria, 
redness or infection signs 
around the injection site 















(n= 84) patients with 
plantar heel pain of at 
least one month's dura-
tion. 
Age: mean ± SD age of 
56.1 ± 12.2 years and 
52% were male. The 
mean ± SD duration of 
plantar heel pain was 
13.6 ± 12.2 months 
(range 1 to 95).  
 
Group 1: (n=42) Real Dry 
needling 
The most frequently treated 
muscles were soleus, gas-
trocnemius, quadratus 
plantae, flexor digitorum 
brevis and abductor hal-
luces. Less frequently nee-
dled muscles included ab-
ductor digiti minimi, and 
flexor hallucis longus. 
Treatments averaged four 
Pain: first step in 
the morning 
(VAS),  FHSQ  
Follow-up: 









voured real dry needling 
over sham dry needling 
for pain (adjusted mean 
difference: VAS first-step 
pain=-14.4 mm, 95% con-
fidence interval [95% 
CI]=-23.5 to -5.2; FHSQ 
foot pain=10.0 points, 
95% CI=1.0 to 19.1) 
 
 
Dry needling provided 
statistically significant 
reduction in PHP. 
 
However, the magnitude 
of this effect should be 
studied against the fre-
quency of minor transito-
















Group 1: (n=42) Real 
Dry needling 
Group 2: (n=42) Sham 
Dry needling  
 
Patients received dry 
needling once per week 




needles per session (range 




























(n=56) workers required 
to stand for greater than 5 
hours/day with chronic 
plantar fasciopathy took 
part. 
Duration of heel pain at 
least 12 months no men-
tion of prior treatment 
Group 1: Physiotherapy-




thasone Injection with 
routine calf stretch.   
The steroid injection pro-
cedure has been described 
previously in the literature. 




with 1ml of dexamethasone 
mixed with 0.5ml of 1% 





136=no disability)  
Secondary out-
come: 100mm 
VAS for patients  
 




The follow-up showed 
significant improvement in 
FADI & VAS compared 
with baseline scores (P < 
0.001).  
 




No significant changes to 
PF thickness reported at 
the 6- and 12-week follow-
up point.  
Both improved significant-
ly in the PHYSIO (P = 
0.003) and INJECTION 
(P < 0.001) groups at 12-
week follow-up. 
 
The study showed that 
prolong standing period 
workers experienced the 
same short-term thera-
peutic effect.  With a 
physiotherapy-led exer-
cise program compared 
with an injection of corti-






















Gender: 47 (77%) wom-
en and 14 (23%) men)  
Mean age of 41.4 12.23 
years (range, 18-60 
years).  
A total of 28 (45.9%) 
left, and 33 (54.1%) right 
feet were studied. 
Single injection for both 
groups 
Group 1: (n= 31) Tenox-
icam group treated with 
local injection of 1 mL of 
Tenoxicam (20 mg/2 
mL) and one mL of 2% 
lidocaine.  
  
Group 2: (n= 30) Steroid 
injection The steroid group 
using a local 1-mL injec-
tion containing 40 mg of 
methylprednisolone acetate 
and one mL of 2% lido-
caine.  
   
 





Mean VAS reduction 
from pre-treatment  o 12 
month post‐treatment was 
statistically significant for 
both groups  
Mean VAS scores of 
tenoxicam group: 8.26 
(pre) → 2.94 (12 month) 
(p < 0.05) 
Steroid group: 7.97 (pre) 
→ 3.17 (12 month) (p < 
0.05) 
No significant difference 
was found between the 
steroid and tenoxicam 
groups in terms of VAS  
 
Tenoxicam is an effec-
tive treatment for PF.  
 
No complications attrib-









(n=40) the pain > 4 





Age: 51.54 (28-77) years 
old 
Gender: 80% women’s  
 




Group 1: BoNT-A injec-
tion 
Botox (200 units) in 2mL 
0.9% saline solution or 
same volume in placebo 
with saline solution’s.  








The participants in the 
BoNT-A group achieved a 
response at the 6th week  
(25% vs. 5% for placebo; 
P=0.18). 
Differences between 
treatments were for 
BoNT-A on secondary 
measures of pain but did 
not reach statistical sig-
nificance. 
Most of the participants in 
the BoNT-A group 
achieved a response at 
 
BoNT-A achieved a good 
response a large prospec-
tive long-term should is 
recommended.  
 
(The author did not stop 
other intervention which 
can be causing some ef-
fects of the treatments, if 
not the control group the 
placebo shall have some 
results which affect the 














itant treatment such as 
the application of ice, 
iontophoresis, ESWT, 
heel cups and orthosis, 
activity modification, or 
stretching/strengthening 
programs, which were 
prescribed before study 
start, was not interrupt-
ed.  
Medication changes were 
not recommended.  
 
week 6 (25% vs. 5% for 
placebo; P=0.18). 
The difference was fa-
vouring the BoNT-A on 
secondary measures of 
pain but did not reach 
statistical significance. In 
the BoNT-A group, 52.7% 
(vs. 40% for placebo) as-
sessed their condition as 
slightly/significantly im-




No adverse events occur 
or was noticed. 
Ball 





(n=65) PHP failed to 
response to 8 weeks of 
conservative therapy, 
excluding previous injec-





Group 3: (n=22) age 
[50.1 (10.6) 11 
males,(52%)] ultrasound 
guided placebo; 1 ml of 
0.9% saline (placebo 
group) was injected 
along the superficial bor-
der of the plantar fascia 
enthesis under direct ul-
trasound guidance. 
Group 1: (n=22) age [49.0 
(12.9) male 10, (45%)] 
 patient received ultrasound 
guided steroid injections  
A 21-gauge needle was 
inserted parallel to the heel 
pad in line with the long 
axis of the transducer, Ei-
ther  
0.5 ml (20 mg) of 
methylprednisolone acetate 
+0.5 ml of 0.9% saline 
(ultrasound guided steroid 
group) or  
 
Group 2: (n=21) age 
[49.1(10.7), males 
8(36%)]patients given 
steroid under palpations  
Pain: VAS (100) 
at 6, 12. 
Change in the PF 










ly in VAS scores between 
the groups at 6 and 12 
weeks (p=0.018 and 
p=0.004, respectively).  
 
19.7 (95% CI 2.5 to 37.0) 
difference in mean VAS 
scores at six weeks be-
tween the US-guided ster-
oid group, & the placebo 
group.  
24.0 (95% CI 6.6 to 41.3) 
difference between the 
unguided steroid group & 
the placebo group at six 
weeks. 
 
 At the 12 weeks, the mean 
Although both ultra-
sound-guided cortico-
steroid injection and 
wearing a full-length 
silicone insole were ef-
fective in the conserva-
tive treatment of plantar 
fasciitis, we recommend 
the use of silicone insoles 
as the first line of treat-
ment for persons with 
plantar fasciitis. 
 
There were no adverse 
events. 
 
Any patient who failed to 
respond clinically to in-















All patients were asked to 
avoid weight bearing on 
the heel pad for 48 h and 
could continue with their 
usual analgesia.  
 
A 21-gauge needle was 
inserted parallel to the heel 
pad in the direction of the 
medial tubercle of the cal-
caneus. An amount of 0.5 
ml (20 mg) of methylpred-
nisolone acetate and 0.5 ml 
of 0.9% saline was injected 
once the needle had been 
inserted to the hilt.  
 
difference was 25.1 (95% 
CI 6.5 to 43.6) and 28.4 
(95% CI 11.1 to 45.7) 
respectively between both 
steroid injection groups 
and the placebo group.  
 
No difference in VAS 
scores following steroid 
injection within the US-
guided & the unguided 
groups at either time 
point.  
 
PF thickness significantly 
reduced after injection in 
both active treatment 
groups (p=0.00). 
Patients in both injection 
groups showed a statisti-
cally significant reduc-
tion in VAS pain scores 
compared with the place-
bo group There were no 
significant differences 
between the steroid 
groups at either time point 
(p = 0.58) VAS score 
difference.  
 
then offered an ultra-
sound guided steroid 
injection outside the trial  
Díaz-
Llopis 
(n=56) patient who un-
dergo for 6 month of 
two different phases; pa-
tients with therapeutic fail-
Functionally and 
Pain: (FHSQ 4 
At 1 month, there was 
significant improvement 
BoTX-A should be con-





















for PF. all patients were 
initially treated with 
stretching, with revision 
after several weeks  
patients with injections in 
the last 6 months were 
excluded.  
Group 1: (n=28) re-
ceived Botox injection 
[BTX, SD 51.50 (14.79), 
9 males (32.14%)] 
 
100 U of botulinum toxin 
type A were diluted in 1 
mL of normal saline and 
70 U were injected: 40 U 
in the tender region of 
the heel medial to the 
insertion of the plantar 
fascia and 30U in the 
area between one inch 
(2.5 cm) distal to the talar 
insertion of the plantar 
fascia and the midpoint 
of the plantar arch  
 
Group 2: (n=28) [CS, 
SD 56.36 (14.71), 10 
males (35.7%)] 
 receive corticosteroid 
injection 
ure after the 1st interven-
tion crosses to the compar-
ator group (after one 
month) duration of heel 
pain at least six months; 
prior conservative treat-
ment (NSAIDs, heel pads, 
insoles, night splints) for at 




group Injection of 40 
units in tender region of 
heel medial to insertion of 
plantar fascia and  
Unguided steroid injec-
tion group 2 mL (12 mg) 
betamethasone acetate + 
0.5 mL 1% mepivacaine 
(LA) in the same tender 
region of the heel and a 
subcutaneous injection of 
placebo (normal saline) in 
the middle of the medial 
side of the fascia  
 
items) foot pain, 
foot function, foot 
shoe, and general 
foot health.  
Follow-up: 1, 6 
months   
 
  
in all the item scores of 
both groups compared to 
baseline, except in item 3 
(shoe) in the steroid injec-
tion group  
Change at 1 month from 
baseline FSHQ1 BTX‐
A: 34.24 (21.10), p < 
0.001 CS: 22.12 (27.42), p 
< 0.001  
FSHQ2  
BTX‐A: 27.45 (20.58), p 
< 0.001 CS: 21.43 
(24.85), p < 0.001  
 
 
of chronic PF, the change 
found by one month, in 
particularly at six 
months, when this treat-
ment clearly has better 
results than corticosteroid 
injections. 
 
There were no early or 
late adverse effects relat-
ed 
to either of the two 














corticosteroid (2 mL of 
betamethasone 6 mg/mL 
(as acetate and disodium 
phosphate)) plus local 
anaesthetic (0.5 mL of 
1% mepivacaine) in the 
same area of the calcane-
al tuberosity. In addition, 
a small sub- cutaneous 
injection of placebo 
(normal saline) was per-
formed in the middle of 
the medial side of the 










(n=61) PF for 6 weeks, 
excluding previous sur-
gery.   
 
Group 2: (n=31) age 
(49.2 ± 11.1) (29 – 66) 
2 males 29 females.  
received corticosteroid 
group.  
A combination of 20 mg 
(0.5 ml of a 40 mg/ml 
solution) of Triamcino-
lone Acetonide with 2 ml 
of Lignocaine HCL 1% 
was used. 
Group 1: (n=30) age (48.3 
± 10.5), range (28 – 65) 4  
males 28 females 
 received autologous blood 
group 
For autologous blood injec-
tion, 1.5 ml of autologous 
blood obtained from the 
antecubital vein, and this 
was combined with 1 ml of 
Lignocaine HCL 2%. Thus, 
for both groups, there was 
an equal volume of injec-
tion solution as well as an 
equal amount of Ligno-









Before treatment, both the 
autologous blood group 
and corticosteroid group 
had similarly high levels 
of pain (p = 0.306). Over 
the 6-month follow-up, a 
significant reduction in 
pain levels was noted in 
both groups (p < 0.0001).  
 
 
Significant difference was 
noticed in VAS in CSI  
6-week p = 0.011 
3-month p = 0.005 
Intralesional autologous 
blood injection is effica-
cious in lowering pain 
and tenderness in chronic 
plantar fasciitis, but cor-
ticosteroid is more supe-
rior concerning speed 
and probably extent of 
improvement 
 
There was no fat pad 
atrophy, infection or rup-
ture of the plantar fascia  
All patients found the 















All patients could walk 
but were advised to avoid 
impact-loading activities, 
such as running or jump-
ing, for at least 10 days. 
Nonsteroidal anti-
inflammatory drugs were 
prescribed for not more 
than 3 days, and ice 
packs were allowed for 
post-injection pain. Ele-
vation of the foot was 
advised for swelling  
 
 
caine HCL used.  
 












(n=20) patients with 
chronic plantar fasciitis, 
Refuse needling and rou-
tine physical therapy 
(e.g., cooling, stretch, 
massage therapy and/or 
footwear modifications),; 
diagnosis of coagulopa-
thy or taking anticoagu-
lants except for acetylsal-
icylic acid at dosages up 
to 325 mg/day  
 
Case Group 1: (n=10) 
Age [Mean SD 
DN: dry needling of MTPs 
one session per week for 
four consecutive weeks. 
Diagnosis of MTPs was 
based on detecting a tender 
spot or nodule in a taut 
band of skeletal muscle. 
Dry needling was based on 
calf muscles trigger points, 
especially four trigger 
points of gastrocnemius 
muscle  
using a dry needle with the 
length of 30-50mm and 
diameter of 0.6mm. Treat-
Pain: VAS (0-10 
cm) , FFI  
Functionally: 
Range of motion 










DN effect was evaluated 
at three-time points of 
baseline, 4 weeks after 




Based on paired t-test, the 
mean VAS scores were 
significantly decreased 
after four weeks of inter-
vention (p<0.001) and 
four weeks of cessation 
period (p<0.001).  
 
There was an insignifi-
cant effect on ROMDF 
and ROMPE, trigger 
point dry needling. 
dry needling and/or in-
jection of therapeutic 
medications (local anaes-
thetics, steroids, botuli-
num toxin A) have been 
studied for plantar 
fasciitis treatment. Of 
these treatment options, 
steroid injections are 
more commonly used in 














(50.3±8.9) 3 male & 7 
females] 
 
Control Group  2: 
(n=10) [4 male & 6 fe-
males (50.9±8.9)]  Con-
trol group  
50 mg diclofenac sodium 
/12 hours and orthostatic 
plantar pad were pre-
scribed for all patients.  
 
All patients were trained 
to do cold ice massage 
and self-stretching for 
four weeks 
ment was conducted within 




ROMDF of ankle joint 
was significantly in-
creased both after four 
weeks of intervention 
(p<0.001) and four weeks 
of cessation period 
(p<0.001).  
 
ROMPE of ankle joint 
was not significant after 
four weeks of intervention 
(p=0.34), the mean 
ROMPE of ankle joint 
was significantly in-
creased after four weeks 




ic plantar fasciitis, espe-
cially when more con-
servative managements 




VAS:  visual analogue scale SFMPQ:  AOFAS: American Orthopedic Foot and Ankle Society , FFI : Foot Function Index ,ESWT: Extracorpo-
real Shock Wave Therapy, ESE: Eccentric stretching exercises. Gy: is a derived unit of ionizing radiation dose in the International System of 
Units, PG: Palpation Guide, PF: Plantar Fasciitis PHP: plantar heel pain. ISI : Intralesional Steroid Injection , AVBI : Autologous Venous Blood 
Injection , AOFAS: American orthopedic foot ankle society , PRP: Platelet Rich Plasma Therapy , FAOS: Foot & Ankle outcome score , 
FHSQ: Foot Health status questioner , TT : Tenderness Threshold, HTI : Heel Tenderness Index , US: Ultrasonography , MSN: Miniscalpel 
needle , PPT: Pain Pressure Threshold , ACP: Autologous condition plasma , FAAM : Foot Ankle Ability Measure , MOXFQ : Manchester Ox-
ford Foot Questioner , PDRN: Polydeoxyribonucleotide , FADI : Foot Ankle Disability Index,  BoNT-A: Botulinum toxin type-A, BTX : Botox , 





























Table 2. Summary of PEDro scale scores   
 
PEDro Scale Score     Number of articles Found 
5/10                                            (n=1) article  
6/10 (n=4) articles 
7/10 (n=12) articles 
8/10 (n=3) articles 
9/10 (n=9) articles 



















































  Author  
 
  
   
        
1 Eslamian, F 
(Eslamian et 
al., 2016b) 
1 1 0 1 0 0 1 1 1 1 7/10 
2 Mardani-Kivi, 
M (Mardani-
Kivi et al., 
2015) 
1 1 1 1 0 0 0 1 1 1 7/10 
3 Canyilmaz, E  
(Canyilmaz et 
al., 2015) 




1 1 1 0 0 0 1 1 1 1 7/10 
5 Kim, E (Kim 
and Lee, 
2014) 
1 1 1 1 1 0 1 1 1 1 9/10 
6 Yucel, U 
(Yucel et al., 
2013)  
1 1 1 0 0 1 1 1 1 1 7/10 
7 Chew, KTL 
(Chew et al., 
2013) 



























































































































9 Huang, YC 
(Huang et al., 
2010b) 
1 1 1 1 0 1 1 1 1 1 9/10 
10 Kalaci, A 
(Kalaci et al., 
2009)  
1 1 1 1 0 1 1 1 1 1 9/10 




1 1 1 1 0 0 1 0 1 1 7/10 
12 Demir G , 
(Demir et al., 
2015) 
1 1 1 1 0 1 1 1 1 1 9/10 
13 Li S , Shen T 




1 1 1 1 0 1 1 1 1 1 9/10 
14 Mahindra P 
(Mahindra et 
al., 2016)  
1 1 1 0 0 0 1 1 1 1 7/10 
15 Crawford F , 
Atkins D 
(Crawford et 
al., 1999)  
1 1 1 1 0 1 1 1 1 1 9/10 
16 Kiter E (Kiter 
et al., 2006b) 
1 1 0 1 0 1 1 1 1 1 8/10 
17 Zhang SP 
(Zhang et al., 
2009) 














18 Yucel I, 
(Yucel et al., 
2010) 
1 1 1 1 0 0 0 1 1 1 7/10 
19 Celik D (Celik et 
al., 2016) 
1 1 1 1 0 0 0 1 1 1 7/10 
20 Jain K (Jain et al., 
2015a) 
1 1 0 0 0 0 1 1 1 0 5/10 
21 Kim JK (Kim 
and Chung, 2015) 
1 1 1 1 0 1 1 1 1 1 9/10 
22 Cotchett MP 
(Cotchett et al., 2011) 
1 1 0 1 0 0 0 1 1 1 6/10 
23 Ryan M 
(Ryan et al., 
2014) 
1 1 1 1 1 1 1 1 0 0 8/10 
24 Guner S 
(Guner et al., 
2013a) 
1 1 1 1 1 1 0 1 0 0 7/10 
25 Peterlein CD 
(Peterlein et al., 
2012b) 
1 1 1 1 0 1 1 1 1 1 9/10 
26 Ball EM  (Ball 
et al., 2012) 
1 1 1 1 0 0 1 1 0 1 7/10 
27 Díaz-Llopis 
IV  (Díaz-Llopis et 
al., 2012)  
1 1 1 1 1 1 0 1 0 0 7/10 
28 Lee TG (Lee and 
Ahmad, 2007) 
1 1 1 1 0 1 1 1 1 1 9/10 
29 Eftekharsadat  
(Eftekharsadat 
et al., 2016)  
 






























• Published in a peer-
reviewed journal between 
January 2000 and March 
2017   
• Human subjects aged 18 
or older presenting to am-
bulatory care   
• English language   
• Treatment of non-acute (≥ 
4 weeks duration) heel 
pain/condition   
• Intervention included at 
least one group with only 
nondrug, nonsurgical 
treatment(s) 
• Randomized controlled 
trial 
 
• Interventions delivered only to hos-
pitalized patients   
• Commentaries/editorials/letters 
• Non-peer-reviewed publications 
• Conference abstracts   
• Case reports/series   
• Pilot RCTs not designed or powered 
to assess effectiveness 
• No treatment outcomes 
• Non-clinical studies   
• Oral or topical medications/surgery 
used in all treatment groups   




































1. Eligibility criteria were specified  
2. Subjects were randomly allocated to groups (in a crossover 
study, subjects were randomly allocated an order in which 
treatments were received)  
3. Allocation was concealed  
4. The groups were similar at baseline regarding the most im-
portant prognostic indicators  
5. There was blinding of all subjects  
6. There was blinding of all therapists who administered the 
therapy  
7. There was blinding of all assessors who measured at least one 
key outcome  
8. Measures of at least one key outcome were obtained from 
more than 85% of the subjects initially allocated to groups  
9. All subjects for whom outcome measures were available re-
ceived the treatment or control condition as allocated or, 
where this was not the case data for at least one ky outcome 
was analysed by “intention to treat”. 
10. The results of between- group statistical comparisons are re-
ported for at least one outcome.  
11. The study provided point measure for both point measure 




















































Figure 3. Flow diagram of studies through the different phases of the review. 
Records identified through 
Databases (n=1141)  



































Filtered by title 
(n = 407) 
(n=734) articles were  
systematic reviews or guide-
lines, non-English language 
articles.  
 
Filtered by abstract 
(n =140) 
 
(n=267) articles were elim-
inated by titles   
 
Filtered by full text  
(n =42) 
 
Records excluded by ab-
stract and full-text due to 
duplication or other reasons 
(no control group. etc.)  
(n=98) 
 




















Figure 4: Schematic diagram to demonstrate the approach to treatment. 
 
 
 
 
 
